Table 2 –

Clinical characteristics

	High-dose N=21	Standard-dose N=25	P value
Exogenous surfactant therapy, n (%)	21 (100)	25 (100)	1
Inotrope, n (%)	2 (10)	7 (28)	0.15
Ventilator days, median (interquartile range)	5 (1–36)	3 (1–24)	0.40
Dexamethasone, n (%)	2 (10)	4 (16)	0.67
Hydrocortisone, n (%)	7 (33)	5 (20)	0.34
Oxygen requirement at 36 weeks postmenstrual age, n (%)	14 (67)	14 (56)	0.55
Patent ductus arteriosus requiring treatment, n (%)	10 (48)	12 (48)	1
Necrotizing enterocolitis, n (%)	2 (10)	3 (12)	1
Retinopathy of prematurity ≥ grade 3, n (%)	2 (10)	3 (12)	1